ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY

被引：0
|
作者：
Hernandez, Alba [1 ]
Calera, Lourdes [1 ]
Alvarez, Maria [1 ]
Hernando, Jorge [1 ]
Torres, Irene [1 ]
Pajares, Isabel [1 ]
Madani, Julia [1 ]
Cebollero, Ana [1 ]
Anton-Torres, Antonio [1 ]
Artal, Angel [1 ]
机构：
[1] Hosp Univ Miguel Servet, Zaragoza, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
erlotinib; second line; wild-type EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.24-036
引用
收藏
页码：S1017 / S1017
页数：1
相关论文
共 50 条
  • [41] A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer
    Zhang, Yong
    Gao, Chao
    Qu, Wei
    Gao, Yongsheng
    Zhu, Shouhui
    Zhang, Shuo
    He, Wei
    Yu, Yonghua
    CANCER INVESTIGATION, 2015, 33 (06) : 241 - 245
  • [42] Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non-Small Cell Lung Carcinoma Cell Lines
    Augustin, Angelique
    Lamerz, Jens
    Meistermann, Helene
    Golling, Sabrina
    Scheiblich, Stefan
    Hermann, Johannes C.
    Duchateau-Nguyen, Guillemette
    Tzouros, Manuel
    Avila, David W.
    Langen, Hanno
    Essioux, Laurent
    Klughammer, Barbara
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (04) : 520 - 529
  • [43] Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer
    Imamura, Yoshito
    Kato, Taketo
    Nomata, Yuji
    Okado, Shoji
    Watanabe, Hiroki
    Kawasumi, Yuta
    Nakanishi, Keita
    Kadomatsu, Yuka
    Ueno, Harushi
    Nakamura, Shota
    Mizuno, Tetsuya
    Hase, Tetsunari
    Tanaka, Ichidai
    Ishii, Makoto
    Yatsuya, Hiroshi
    Chen-yoshikawa, Toyofumi Fengshi
    ANTICANCER RESEARCH, 2024, 44 (08) : 3451 - 3461
  • [44] Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer
    Felip, Enriqueta
    Metro, Giulio
    Tan, Daniel S. W.
    Wolf, Juergen
    Mark, Michael
    Boyer, Michael
    Hughes, Brett G. M.
    Bearz, Alessandra
    Moro-Sibilot, Denis
    Le, Xiuning
    Puente, Javier
    Massuti, Bartomeu
    Tiedt, Ralph
    Wang, Yingying
    Xu, Chao
    Mardjuadi, Feby I.
    Cobo, Manuel
    LUNG CANCER, 2024, 192
  • [45] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
    Li, Amin
    Cao, Weiya
    Liu, Xueke
    Zhang, Yinci
    Ma, Yongfang
    Xu, Ruyue
    Zhang, Rongbo
    Liu, Xinkuang
    Zhou, Shuping
    Wang, Ruikai
    Liu, Jiachang
    Tang, Xiaolong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (07) : 1737 - 1749
  • [46] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
    Amin Li
    Weiya Cao
    Xueke Liu
    Yinci Zhang
    Yongfang Ma
    Ruyue Xu
    Rongbo Zhang
    Xinkuang Liu
    Shuping Zhou
    Ruikai Wang
    Jiachang Liu
    Xiaolong Tang
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1737 - 1749
  • [47] Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis
    Franchina, T.
    Adamo, B.
    Caristi, N.
    Chiofalo, G.
    Toscano, G.
    Colonese, F.
    Denaro, N.
    Ricciardi, G. R.
    Russo, A.
    Adamo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Second line erlotinib therapy in a non-smoking patient with metastatic non-small-cel lung cancer harbouring EGFR mutation
    Skoczek, Marta
    Czyzewicz, Grzegorz
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G56 - G59
  • [49] Erlotinib in non-small cell lung cancer (NSCLC) in Germany - A cost-saving second-line treatment option?
    Gabriel, A.
    Pirk, O.
    Kotowa, W.
    VALUE IN HEALTH, 2006, 9 (06) : A278 - A278
  • [50] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
    Garassino, Marina Chiara
    Martelli, Olga
    Broggini, Massimo
    Farina, Gabriella
    Veronese, Silvio
    Rulli, Eliana
    Bianchi, Filippo
    Bettini, Anna
    Longo, Flavia
    Moscetti, Luca
    Tomirotti, Maurizio
    Marabese, Mirko
    Ganzinelli, Monica
    Lauricella, Calogero
    Labianca, Roberto
    Floriani, Irene
    Giaccone, Giuseppe
    Torri, Valter
    Scanni, Alberto
    Marsoni, Silvia
    LANCET ONCOLOGY, 2013, 14 (10): : 981 - 988
12345